fashion -WSS

fashion

author：leisure time 2025-09-28 02:28:08 - browse：76931

An AstraZeneca sign at ESMO in Madrid. — An AstraZeneca ad at ESMO 2023 in Madrid. Andrew Joseph/STAT

MADRID — Questions about one of AstraZeneca’s key cancer drug candidates — and the dribs and drabs that have come out about its performance — have been dogging the company for months.

On Monday, data presented here from a trial of the drug in advanced non-small cell lung cancer provided at least a fuller look. While the results assuaged some of the safety fears that flared when initial information was released over the summer, they only heightened concerns about the drug’s ability to outperform standard chemotherapy — though they perhaps pointed to an opportunity for the drug in a subset of patients.

The trial, detailed here in a prime session at the annual meeting of the European Society for Medical Oncology, is testing a therapy called datopotamab deruxtecan, or Dato-DXd, in advanced or metastatic non-small cell lung cancer in patients who already tried at least first-line treatments. Patients were randomized to either receive chemotherapy or Dato-DXd, which AstraZeneca is developing with Daiichi Sankyo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Inaction leaves children at risk from dangerous chemotherapy drug

WSS

FDA approves potent Eli Lilly obesity drug, Zepbound

UCSF medical school apologizes for unethical prisoner experiments

Immunocompromised patients offer clues on chronic Covid

Study: New antibiotic targets gonorrhea as well as last existing drug

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

The new shift in health care is toward less care

focus

fashion

explore

DIEP, the 'gold standard' of breast reconstruction, is under threat

Medicare solvency divides Republicans at the presidential debate

23andMe had bad news about my health. I wish a person had delivered it

Sanofi CEO defends move to abandon profit guidance, boost research

Apple is now the first public company to be valued at $3 trillion

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Victims of gun violence feel impacts long after bullet wound

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Head of FDA's diagnostics center, who led through Covid, retires

entertainment

TikTok, Instagram influencers need more rules for drug ads

White House calls on federal agencies to crack down on AI abuses

A clever new way to fix Medicaid and graduate medical education

High breast density mammograms need follow

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

knowledge

knowledge

hotspot

hotspot